These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 14679129)

  • 1. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
    Comoli P; De Palma R; Siena S; Nocera A; Basso S; Del Galdo F; Schiavo R; Carminati O; Tagliamacco A; Abbate GF; Locatelli F; Maccario R; Pedrazzoli P
    Ann Oncol; 2004 Jan; 15(1):113-7. PubMed ID: 14679129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
    Louis CU; Straathof K; Bollard CM; Ennamuri S; Gerken C; Lopez TT; Huls MH; Sheehan A; Wu MF; Liu H; Gee A; Brenner MK; Rooney CM; Heslop HE; Gottschalk S
    J Immunother; 2010; 33(9):983-90. PubMed ID: 20948438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
    Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy.
    Smith C; Tsang J; Beagley L; Chua D; Lee V; Li V; Moss DJ; Coman W; Chan KH; Nicholls J; Kwong D; Khanna R
    Cancer Res; 2012 Mar; 72(5):1116-25. PubMed ID: 22282657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.
    Chia WK; Teo M; Wang WW; Lee B; Ang SF; Tai WM; Chee CL; Ng J; Kan R; Lim WT; Tan SH; Ong WS; Cheung YB; Tan EH; Connolly JE; Gottschalk S; Toh HC
    Mol Ther; 2014 Jan; 22(1):132-9. PubMed ID: 24297049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients.
    Lutzky VP; Davis JE; Crooks P; Corban M; Smith MC; Elliott M; Morrison L; Cross S; Tscharke D; Panizza B; Coman W; Bharadwaj M; Moss DJ
    Immunol Cell Biol; 2009; 87(6):481-8. PubMed ID: 19468283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.
    Straathof KC; Bollard CM; Popat U; Huls MH; Lopez T; Morriss MC; Gresik MV; Gee AP; Russell HV; Brenner MK; Rooney CM; Heslop HE
    Blood; 2005 Mar; 105(5):1898-904. PubMed ID: 15542583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro induced and expanded Epstein Barr virus-specific cytotoxic T lymphocytes can specifically kill nasopharyngeal carcinoma cells].
    Chen LP; Huang JQ; Zhou TC; Zhang SX; Wang JL
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1431-3. PubMed ID: 18753079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
    Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
    Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.
    Louis CU; Straathof K; Bollard CM; Gerken C; Huls MH; Gresik MV; Wu MF; Weiss HL; Gee AP; Brenner MK; Rooney CM; Heslop HE; Gottschalk S
    Blood; 2009 Mar; 113(11):2442-50. PubMed ID: 18971421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy.
    He J; Tang XF; Chen QY; Mai HQ; Huang ZF; Li J; Zeng YX
    Chin J Cancer; 2012 Jun; 31(6):287-94. PubMed ID: 22257383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
    Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
    Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells.
    Lee SP; Chan AT; Cheung ST; Thomas WA; CroomCarter D; Dawson CW; Tsai CH; Leung SF; Johnson PJ; Huang DP
    J Immunol; 2000 Jul; 165(1):573-82. PubMed ID: 10861098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE; Moss DJ
    Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
    Bollard CM; Straathof KC; Huls MH; Leen A; Lacuesta K; Davis A; Gottschalk S; Brenner MK; Heslop HE; Rooney CM
    J Immunother; 2004; 27(4):317-27. PubMed ID: 15235393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for Epstein-Barr virus-associated cancers in children.
    Straathof KC; Bollard CM; Rooney CM; Heslop HE
    Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
    Bollard CM; Aguilar L; Straathof KC; Gahn B; Huls MH; Rousseau A; Sixbey J; Gresik MV; Carrum G; Hudson M; Dilloo D; Gee A; Brenner MK; Rooney CM; Heslop HE
    J Exp Med; 2004 Dec; 200(12):1623-33. PubMed ID: 15611290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
    J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.